Biogen Inc. (NASDAQ:BIIB) Shares Bought by Clarius Group LLC

Clarius Group LLC boosted its holdings in shares of Biogen Inc. (NASDAQ:BIIB) by 5.6% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 1,123 shares of the biotechnology company’s stock after buying an additional 60 shares during the quarter. Clarius Group LLC’s holdings in Biogen were worth $291,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also bought and sold shares of the company. Altshuler Shaham Ltd acquired a new position in Biogen during the fourth quarter valued at $25,000. OFI Invest Asset Management acquired a new position in shares of Biogen in the 3rd quarter valued at about $26,000. Gladius Capital Management LP purchased a new stake in shares of Biogen in the third quarter worth about $28,000. KB Financial Partners LLC grew its holdings in Biogen by 105.1% during the third quarter. KB Financial Partners LLC now owns 121 shares of the biotechnology company’s stock worth $31,000 after acquiring an additional 62 shares during the period. Finally, CVA Family Office LLC purchased a new position in Biogen during the fourth quarter valued at approximately $36,000. 87.93% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities research analysts have recently commented on the stock. BMO Capital Markets dropped their price objective on shares of Biogen from $295.00 to $285.00 and set an “outperform” rating on the stock in a research note on Wednesday, February 14th. Needham & Company LLC dropped their price target on shares of Biogen from $305.00 to $300.00 and set a “buy” rating on the stock in a research report on Tuesday, February 13th. JPMorgan Chase & Co. decreased their price objective on shares of Biogen from $270.00 to $240.00 and set a “neutral” rating for the company in a research report on Thursday. Barclays dropped their target price on Biogen from $230.00 to $215.00 and set an “equal weight” rating on the stock in a research report on Thursday, April 4th. Finally, William Blair restated an “outperform” rating on shares of Biogen in a research note on Monday, April 1st. Ten research analysts have rated the stock with a hold rating and nineteen have issued a buy rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $298.96.

Biogen Stock Down 2.7 %

BIIB stock opened at $198.18 on Monday. The company’s 50 day moving average price is $220.04 and its 200 day moving average price is $237.74. The company has a debt-to-equity ratio of 0.46, a quick ratio of 1.26 and a current ratio of 2.00. Biogen Inc. has a fifty-two week low of $197.78 and a fifty-two week high of $319.76. The firm has a market capitalization of $28.81 billion, a price-to-earnings ratio of 24.83, a PEG ratio of 1.66 and a beta of -0.02.

Biogen (NASDAQ:BIIB) last announced its quarterly earnings data on Tuesday, February 13th. The biotechnology company reported $2.95 EPS for the quarter, missing analysts’ consensus estimates of $3.18 by ($0.23). Biogen had a return on equity of 14.91% and a net margin of 11.81%. The firm had revenue of $2.39 billion for the quarter, compared to analysts’ expectations of $2.47 billion. During the same quarter in the previous year, the company posted $4.05 EPS. On average, equities research analysts anticipate that Biogen Inc. will post 15.45 EPS for the current fiscal year.

Insider Transactions at Biogen

In other news, Director Eric K. Rowinsky acquired 455 shares of Biogen stock in a transaction that occurred on Thursday, February 15th. The stock was purchased at an average cost of $222.54 per share, with a total value of $101,255.70. Following the completion of the acquisition, the director now owns 20,629 shares in the company, valued at approximately $4,590,777.66. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In related news, insider Priya Singhal sold 419 shares of the company’s stock in a transaction that occurred on Monday, February 12th. The stock was sold at an average price of $239.45, for a total value of $100,329.55. Following the sale, the insider now owns 4,516 shares of the company’s stock, valued at approximately $1,081,356.20. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, Director Eric K. Rowinsky purchased 455 shares of the company’s stock in a transaction on Thursday, February 15th. The shares were bought at an average cost of $222.54 per share, with a total value of $101,255.70. Following the transaction, the director now directly owns 20,629 shares of the company’s stock, valued at approximately $4,590,777.66. The disclosure for this purchase can be found here. Insiders have sold 882 shares of company stock valued at $202,030 in the last quarter. 0.60% of the stock is currently owned by corporate insiders.

Biogen Company Profile

Biogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS.